Vertex Pharmaceuticals Inc (VRTX) Inventory Turnover Ratio, from second quarter 2026 to second quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 
Vertex Pharmaceuticals Inc  (NASDAQ: VRTX)
 

Vertex Pharmaceuticals Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Vertex Pharmaceuticals Inc inventory turnover ratio, the Vertex Pharmaceuticals Inc's ability to sell and replace its inventory in the second quarter 2026, sequentially increased to 1.03 in the second quarter 2026, yet the ratio remained below the average, as VRTX's market remain challenging.Average inventory processing period, for the Vertex Pharmaceuticals Inc in Jun 30 2026 quarter, has decreased to 354 days, compare to 358 days, in the Mar 31 2026 quarter.

Within Healthcare sector 309 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 1128 in the first quarter 2026, to 1798.

VRTX Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Vertex Pharmaceuticals Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VRTX Inventory Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Inventory Growth 17.73 % 29.93 % 39.94 % 50.66 % 63.93 %
Y / Y Cost of Sales Growth 20.05 % 8.21 % 10.06 % 5.65 % 9.57 %
Inventory Turnover Ratio (TTM) 1.03 1.02 1.07 1.13 1.23
VRTX's Total Ranking # 1798 # 1128 # 530 # 1538 # 1056
Average inventory processing period 354 357 341 323 296
Seq. Inventory Growth -0.09 % 4.74 % 3.69 % 8.5 % 10.27 %
Seq. Cost of Sales Growth 24.54 % -15.71 % 12.34 % 1.79 % 12.26 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 90
Healthcare Sector # 310
Overall Market # 1798

Inventory Turnover Ratio Statistics
High Average Low
9.21 3.02 1.02
(Sep 30 2013)   (Mar 31 2026)



VRTX Company Profile >> Back to VRTX Efficiency Comparisons >> Compare VRTX Inventory Turnover Ratio to its Competitors

Financial Statements
Vertex Pharmaceuticals Inc's Inventories $ 1,765 Millions Visit VRTX's Balance sheet
Vertex Pharmaceuticals Inc's Cost of Revenues TTM $ 1,763 Millions Visit VRTX's Income Statement
What are VRTX's Sales? Visit VRTX's Sales by Segment

Other Inventory Turnover Ratios
Vertex Pharmaceuticals Inc's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
VRTX's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for VRTX's Competitors
Inventory Turnover Ratio for VRTX's Suppliers
Inventory Turnover Ratio for VRTX's Customers

You may also want to know
VRTX's Sales Growth Rates VRTX's Pe Price to earnings ratio VRTX's Receivables Turnover Ratio VRTX's Stock Quote
VRTX's Net Income Growth Rates VRTX's Ps Price to Sales ratio VRTX's Sales per Employee VRTX's Asset Turnover Ratio
VRTX's Net Margin VRTX's Pb Price to Book ratio VRTX's Financial Strength Ratios VRTX's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Jun 30 2026 Inventories at quarter ending Jun 30 2026
Ani Pharmaceuticals Inc  2.69 $ 387.398  Millions$ 144  Millions
Neogen Corporation  2.67 $ 461.474  Millions$ 173  Millions
Innoviva Inc   2.65 $ 102.975  Millions$ 39  Millions
Vycor Medical Inc   2.64 $ 0.301  Millions$ 0  Millions
International Stem Cell Corporation  2.61 $ 4.285  Millions$ 2  Millions
Biomerica Inc   2.59 $ 4.091  Millions$ 2  Millions
Evofem Biosciences Inc   2.58 $ 4.418  Millions$ 2  Millions
Indivior Pharmaceuticals Inc   2.55 $ 240.000  Millions$ 94  Millions
Nephros Inc   2.54 $ 8.991  Millions$ 4  Millions
Illumina Inc   2.52 $ 1,510.000  Millions$ 599  Millions
IMPACT BIOMEDICAL INC.  2.46 $ 0.414  Millions$ 0  Millions
Quidelortho Corp  2.45 $ 1,481.500  Millions$ 605  Millions
Cumberland Pharmaceuticals Inc   2.44 $ 5.164  Millions$ 2  Millions
Perrigo Company Plc  2.43 $ 2,775.900  Millions$ 1,140  Millions
Pro dex Inc   2.43 $ 53.213  Millions$ 22  Millions
Angiodynamics Inc   2.43 $ 142.834  Millions$ 59  Millions
Cytosorbents Corporation  2.43 $ 10.584  Millions$ 4  Millions
Journey Medical Corp  2.42 $ 23.556  Millions$ 10  Millions
Aquestive Therapeutics Inc   2.42 $ 17.828  Millions$ 7  Millions
Viatris Inc   2.41 $ 9,604.200  Millions$ 3,993  Millions
Electrocore Inc   2.40 $ 4.346  Millions$ 2  Millions
United Therapeutics Corporation  2.39 $ 437.200  Millions$ 183  Millions
Cannapharmarx Inc   2.37 $ 2.483  Millions$ 1  Millions
Aurinia Pharmaceuticals Inc   2.34 $ 30.036  Millions$ 13  Millions
Fortress Biotech Inc   2.34 $ 22.768  Millions$ 10  Millions
Scientific Industries Inc   2.33 $ 4.057  Millions$ 2  Millions
Resmed Inc   2.33 $ 2,176.428  Millions$ 933  Millions
Insight Molecular Diagnostics Inc   2.31 $ 0.868  Millions$ 0  Millions
Merit Medical Systems Inc  2.30 $ 798.467  Millions$ 347  Millions
Tela Bio Inc   2.30 $ 26.348  Millions$ 11  Millions

Date modified: 2026-09-02T20:09:09+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.